From the University of Pittsburgh School of Medicine, Pittsburgh, PA (CLB, MN, ABD) and University of New Mexico, Center on Alcohol, Substance use, and Addictions (CASAA), Albuquerque, NM (CLB).
J Am Board Fam Med. 2022 Mar-Apr;35(2):420-426. doi: 10.3122/jabfm.2022.02.210327.
Severe acute respiratory syndrome coronavirus 2, or coronavirus disease 2019 (COVID-19), vaccine hesitancy, defined as a behavioral phenomenon whereby individuals neither fully accept nor fully reject the COVID-19 vaccine, presents a major health threat in the midst of the current pandemic. Traditional approaches for addressing vaccine hesitancy in health care lack empirical support and, in some instances, have actually vaccine hesitancy. Thus, there is an urgent need for approaches that effectively address COVID-19 vaccine hesitancy, especially in health care settings. The current article highlights the need for and importance of motivational interviewing (MI), which emphasizes collaborative communication between physicians and patients, in addressing vaccine hesitancy. We describe a 3-step process for addressing COVID-19 vaccine hesitancy that includes using a guiding style, using the MI toolbox, and responding mindfully and skillfully to the individual's degree of hesitancy. The discussion concludes with a consideration of possible challenges in implementing these steps when addressing and resolving COVID-19 vaccine hesitancy.
严重急性呼吸综合征冠状病毒 2 型,或 2019 年冠状病毒病(COVID-19)疫苗犹豫,定义为一种行为现象,即个体既不完全接受也不完全拒绝 COVID-19 疫苗,在当前大流行期间构成重大健康威胁。传统的医疗保健疫苗犹豫应对方法缺乏经验支持,在某些情况下实际上加剧了疫苗犹豫。因此,迫切需要有效的方法来解决 COVID-19 疫苗犹豫问题,尤其是在医疗保健环境中。本文强调了在解决疫苗犹豫问题方面,特别是在医疗保健环境中,需要并重视动机性访谈(MI),它强调医生和患者之间的协作沟通。我们描述了一个解决 COVID-19 疫苗犹豫的 3 步流程,包括使用引导式风格、使用 MI 工具包,以及有意识和巧妙地回应个体的犹豫程度。讨论最后考虑了在解决和解决 COVID-19 疫苗犹豫时实施这些步骤可能面临的挑战。